Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis

Overview

Journal Clin Med Insights Arthritis Musculoskelet Disord

Publisher Sage Publications

Specialty Rheumatology

Date 2012 Jan 24

PMID 22267947

Citations 2

Authors

Brian J Gates

Shyamal Das

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Osteoporosis is a significant concern for postmenopausal women and is a critical factor in hip fracture. Examining evidence for osteoporosis medications in hip fracture is important for optimizing treatment.

Purpose: Review risedronate's role for hip fracture in postmenopausal women.

Methods: A literature search was conducted using Medline and Web of Science. The search was limited using the terms "risedronate" and "hip fracture," and to studies that included women. Similar articles linked to the search and pertinent articles in bibliographies were also examined.

Results: Risedronate has demonstrated efficacy and cost effectiveness for hip fracture, but may not be beneficial for patients with low fracture risk. Risedronate is generally well tolerated, but may cause side effects in some patient populations.

Conclusion: Risedronate has benefit for hip fracture, but patients should be carefully screened to determine the appropriateness of risedronate before starting treatment.

Citing Articles

Identifying Key Genes and Functionally Enriched Pathways in Osteoporotic Patients by Weighted Gene Co-Expression Network Analysis.

Fan P, Feng X, Hu N, Pu D, He L Biochem Genet. 2023; 62(1):436-451.

PMID: 37358674 DOI: 10.1007/s10528-023-10425-6.

Alterations in DNA methylation profiles in cancellous bone of postmenopausal women with osteoporosis.

Zhou Y, Yang L, Wang H, Chen X, Jiang W, Wang Z FEBS Open Bio. 2020; 10(8):1516-1531.

PMID: 32496000 PMC: 7396431. DOI: 10.1002/2211-5463.12907.

References

Curtis J, Westfall A, Cheng H, Saag K, Delzell E . RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int. 2008; 20(6):973-8. PMC: 2711629. DOI: 10.1007/s00198-008-0772-2. View

Maclean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2007; 148(3):197-213. DOI: 10.7326/0003-4819-148-3-200802050-00198. View

Adachi J, Adami S, Miller P, Olszynski W, Kendler D, Silverman S . Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano). 2002; 13(5):347-54. DOI: 10.1007/BF03351502. View

Body J, Bergmann P, Boonen S, Boutsen Y, Devogelaer J, Goemaere S . Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int. 2010; 21(10):1657-80. PMC: 2931762. DOI: 10.1007/s00198-010-1223-4. View

Russell R, Watts N, Ebetino F, Rogers M . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19(6):733-59. DOI: 10.1007/s00198-007-0540-8. View

Russell R, Muhlbauer R, BISAZ S, Williams D, Fleisch H . The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised.... Calcif Tissue Res. 1970; 6(3):183-96. DOI: 10.1007/BF02196199. View

Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S . 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182(17):1864-73. PMC: 2988535. DOI: 10.1503/cmaj.100771. View

Raef H, Al-Bugami M, Balharith S, Moawad M, El-Shaker M, Hassan A . Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med. 2011; 31(2):111-28. PMC: 3102469. DOI: 10.4103/0256-4947.77502. View

Dunford J, Thompson K, Coxon F, Luckman S, Hahn F, Poulter C . Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296(2):235-42. View

10.

Liberman U, Hochberg M, Geusens P, Shah A, Lin J, Chattopadhyay A . Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract. 2006; 60(11):1394-400. DOI: 10.1111/j.1742-1241.2006.01148.x. View

11.

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

12.

Sorensen O, Crawford G, Mulder H, Hosking D, Gennari C, Mellstrom D . Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003; 32(2):120-6. DOI: 10.1016/s8756-3282(02)00946-8. View

13.

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

14.

Pazianas M, Cooper C, Ebetino F, Russell R . Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010; 6:325-43. PMC: 2909499. DOI: 10.2147/tcrm.s8054. View

15.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

16.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. DOI: 10.1002/14651858.CD004523.pub3. View

17.

Compston J, Cooper A, Cooper C, Francis R, Kanis J, Marsh D . Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62(2):105-8. DOI: 10.1016/j.maturitas.2008.11.022. View

18.

Silverman S, Watts N, Delmas P, Lange J, Lindsay R . Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2006; 18(1):25-34. PMC: 1705543. DOI: 10.1007/s00198-006-0274-z. View

19.

Doherty D, Sanders K, Kotowicz M, Prince R . Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int. 2001; 12(1):16-23. DOI: 10.1007/s001980170152. View

20.

Ste-Marie L, Brown J, Beary J, Matzkin E, Darbie L, Burgio D . Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Clin Ther. 2009; 31(2):272-85. DOI: 10.1016/j.clinthera.2009.02.012. View